nodes	percent_of_prediction	percent_of_DWPC	metapath
Phentolamine—ADRA1A—Endothelin Pathways—ADCY10—nephrolithiasis	0.0484	0.0599	CbGpPWpGaD
Phentolamine—ADRA1D—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0273	0.0337	CbGpPWpGaD
Phentolamine—Peptic ulcer—Hydrochlorothiazide—nephrolithiasis	0.0269	0.14	CcSEcCtD
Phentolamine—ADRA2B—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0246	0.0304	CbGpPWpGaD
Phentolamine—ADRA2C—Monoamine GPCRs—CHRM3—nephrolithiasis	0.023	0.0284	CbGpPWpGaD
Phentolamine—ADRA1D—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0229	0.0283	CbGpPWpGaD
Phentolamine—ADRA1B—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0226	0.028	CbGpPWpGaD
Phentolamine—ADRA2B—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0207	0.0256	CbGpPWpGaD
Phentolamine—ADRA1A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0201	0.0249	CbGpPWpGaD
Phentolamine—ADRA2C—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0193	0.0239	CbGpPWpGaD
Phentolamine—ADRA1B—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.019	0.0235	CbGpPWpGaD
Phentolamine—ADRA2A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0187	0.0231	CbGpPWpGaD
Phentolamine—ADRA1A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0169	0.0209	CbGpPWpGaD
Phentolamine—ADRA1D—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.0167	0.0207	CbGpPWpGaD
Phentolamine—ADRA2A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0157	0.0194	CbGpPWpGaD
Phentolamine—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.0143	0.0748	CcSEcCtD
Phentolamine—ADRA1B—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.0139	0.0172	CbGpPWpGaD
Phentolamine—ADRA1A—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.0123	0.0152	CbGpPWpGaD
Phentolamine—ADRA1D—GPCRs, Other—CHRM3—nephrolithiasis	0.0121	0.015	CbGpPWpGaD
Phentolamine—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.0119	0.0622	CcSEcCtD
Phentolamine—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.0119	0.0622	CcSEcCtD
Phentolamine—ADRA2C—Regulation of insulin secretion—CHRM3—nephrolithiasis	0.0117	0.0144	CbGpPWpGaD
Phentolamine—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.011	0.0573	CcSEcCtD
Phentolamine—ADRA2B—G alpha (i) signalling events—RGS14—nephrolithiasis	0.0105	0.013	CbGpPWpGaD
Phentolamine—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00992	0.0517	CcSEcCtD
Phentolamine—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00986	0.0514	CcSEcCtD
Phentolamine—ADRA2C—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00979	0.0121	CbGpPWpGaD
Phentolamine—ADRA2A—Regulation of insulin secretion—CHRM3—nephrolithiasis	0.00948	0.0117	CbGpPWpGaD
Phentolamine—ADRA1D—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00941	0.0116	CbGpPWpGaD
Phentolamine—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00919	0.048	CcSEcCtD
Phentolamine—ADRA2C—Integration of energy metabolism—CHRM3—nephrolithiasis	0.00918	0.0114	CbGpPWpGaD
Phentolamine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00842	0.0104	CbGpPWpGaD
Phentolamine—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00838	0.0437	CcSEcCtD
Phentolamine—ADRA1D—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00816	0.0101	CbGpPWpGaD
Phentolamine—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00807	0.0421	CcSEcCtD
Phentolamine—ADRA2A—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00795	0.00984	CbGpPWpGaD
Phentolamine—ADRA1B—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00781	0.00966	CbGpPWpGaD
Phentolamine—ADRA2A—Integration of energy metabolism—CHRM3—nephrolithiasis	0.00745	0.00922	CbGpPWpGaD
Phentolamine—ADRA2B—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00743	0.0092	CbGpPWpGaD
Phentolamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00699	0.00864	CbGpPWpGaD
Phentolamine—ADRA2C—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00694	0.00859	CbGpPWpGaD
Phentolamine—ADRA1A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00694	0.00858	CbGpPWpGaD
Phentolamine—ADRA1D—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0068	0.00842	CbGpPWpGaD
Phentolamine—ADRA1B—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00677	0.00838	CbGpPWpGaD
Phentolamine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00669	0.0349	CcSEcCtD
Phentolamine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00626	0.0327	CcSEcCtD
Phentolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00621	0.00768	CbGpPWpGaD
Phentolamine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00609	0.00753	CbGpPWpGaD
Phentolamine—ADRA1A—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00602	0.00744	CbGpPWpGaD
Phentolamine—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00599	0.0313	CcSEcCtD
Phentolamine—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00576	0.0301	CcSEcCtD
Phentolamine—ADRA1B—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00565	0.00699	CbGpPWpGaD
Phentolamine—ADRA2A—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00564	0.00698	CbGpPWpGaD
Phentolamine—Pain—Hydrochlorothiazide—nephrolithiasis	0.00549	0.0286	CcSEcCtD
Phentolamine—ADRA1D—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00526	0.00651	CbGpPWpGaD
Phentolamine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00525	0.0274	CcSEcCtD
Phentolamine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00507	0.0265	CcSEcCtD
Phentolamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00505	0.00625	CbGpPWpGaD
Phentolamine—ADRA1A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00502	0.00621	CbGpPWpGaD
Phentolamine—ADRA2B—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00475	0.00587	CbGpPWpGaD
Phentolamine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.0046	0.024	CcSEcCtD
Phentolamine—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00454	0.0237	CcSEcCtD
Phentolamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00451	0.00558	CbGpPWpGaD
Phentolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00449	0.00555	CbGpPWpGaD
Phentolamine—ADRA2C—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00444	0.00549	CbGpPWpGaD
Phentolamine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00439	0.0229	CcSEcCtD
Phentolamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00437	0.0054	CbGpPWpGaD
Phentolamine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00424	0.0221	CcSEcCtD
Phentolamine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00408	0.0213	CcSEcCtD
Phentolamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00407	0.00503	CbGpPWpGaD
Phentolamine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00402	0.021	CcSEcCtD
Phentolamine—ADRA1D—GPCR downstream signaling—RGS14—nephrolithiasis	0.00397	0.00491	CbGpPWpGaD
Phentolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00388	0.0048	CbGpPWpGaD
Phentolamine—ADRA2B—Hemostasis—SLC7A9—nephrolithiasis	0.00383	0.00474	CbGpPWpGaD
Phentolamine—ADRA2B—Hemostasis—DGKH—nephrolithiasis	0.00383	0.00474	CbGpPWpGaD
Phentolamine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00381	0.0199	CcSEcCtD
Phentolamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.0038	0.0047	CbGpPWpGaD
Phentolamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00374	0.00463	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—RGS14—nephrolithiasis	0.00361	0.00446	CbGpPWpGaD
Phentolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.0036	0.00446	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—RGS14—nephrolithiasis	0.00359	0.00444	CbGpPWpGaD
Phentolamine—ADRA2C—Hemostasis—SLC7A9—nephrolithiasis	0.00358	0.00443	CbGpPWpGaD
Phentolamine—ADRA2C—Hemostasis—DGKH—nephrolithiasis	0.00358	0.00443	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR ligand binding—CHRM3—nephrolithiasis	0.00343	0.00425	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—RGS14—nephrolithiasis	0.00335	0.00414	CbGpPWpGaD
Phentolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00332	0.00411	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—RGS14—nephrolithiasis	0.0033	0.00408	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—RGS14—nephrolithiasis	0.00326	0.00403	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR ligand binding—PTH—nephrolithiasis	0.00314	0.00388	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR ligand binding—CHRM3—nephrolithiasis	0.0031	0.00383	CbGpPWpGaD
Phentolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00309	0.00382	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—RGS14—nephrolithiasis	0.00304	0.00376	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—RGS14—nephrolithiasis	0.00299	0.0037	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—RGS14—nephrolithiasis	0.00293	0.00362	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—DGKH—nephrolithiasis	0.00291	0.0036	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—SLC7A9—nephrolithiasis	0.00291	0.0036	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—CHRM3—nephrolithiasis	0.00289	0.00358	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—CHRM3—nephrolithiasis	0.00285	0.00352	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR ligand binding—PTH—nephrolithiasis	0.00283	0.00351	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.00272	0.00337	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—DGKH—nephrolithiasis	0.00268	0.00332	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—RGS14—nephrolithiasis	0.00266	0.00329	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—PTH—nephrolithiasis	0.00265	0.00327	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—PTH—nephrolithiasis	0.00261	0.00322	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—CHRM3—nephrolithiasis	0.00253	0.00313	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—ADCY10—nephrolithiasis	0.00251	0.0031	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—RGS14—nephrolithiasis	0.00247	0.00306	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—DGKH—nephrolithiasis	0.00244	0.00301	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—DGKH—nephrolithiasis	0.00242	0.003	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.00235	0.00291	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—PTH—nephrolithiasis	0.00231	0.00286	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—DGKH—nephrolithiasis	0.00226	0.0028	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—ADCY10—nephrolithiasis	0.00226	0.0028	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—DGKH—nephrolithiasis	0.00223	0.00275	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—DGKH—nephrolithiasis	0.0022	0.00272	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—PTH—nephrolithiasis	0.00215	0.00266	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—GRHPR—nephrolithiasis	0.00215	0.00266	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—RGS14—nephrolithiasis	0.00213	0.00264	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—ADCY10—nephrolithiasis	0.00211	0.00261	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—ADCY10—nephrolithiasis	0.00208	0.00257	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—DGKH—nephrolithiasis	0.00205	0.00254	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—DGKH—nephrolithiasis	0.00202	0.0025	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—DGKH—nephrolithiasis	0.00198	0.00245	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00194	0.0024	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—RGS14—nephrolithiasis	0.00192	0.00238	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—AGXT—nephrolithiasis	0.00192	0.00237	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—ADCY10—nephrolithiasis	0.00185	0.00229	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.00184	0.00227	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—RGS14—nephrolithiasis	0.0018	0.00222	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—DGKH—nephrolithiasis	0.0018	0.00222	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—PTH—nephrolithiasis	0.00177	0.00219	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—RGS14—nephrolithiasis	0.00177	0.00219	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—CHRM3—nephrolithiasis	0.00176	0.00218	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00175	0.00217	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—GRHPR—nephrolithiasis	0.00175	0.00216	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ADCY10—nephrolithiasis	0.00172	0.00212	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—DGKH—nephrolithiasis	0.00167	0.00206	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00164	0.00202	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—APRT—nephrolithiasis	0.00163	0.00201	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—SLC26A1—nephrolithiasis	0.00163	0.00201	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—PTH—nephrolithiasis	0.00161	0.00199	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00161	0.00199	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—PTH—nephrolithiasis	0.0016	0.00198	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—CHRM3—nephrolithiasis	0.00159	0.00197	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—RGS14—nephrolithiasis	0.00157	0.00194	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—AGXT—nephrolithiasis	0.00156	0.00192	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—PTH—nephrolithiasis	0.0015	0.00185	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—CHRM3—nephrolithiasis	0.00149	0.00184	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—PTH—nephrolithiasis	0.00147	0.00182	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—CHRM3—nephrolithiasis	0.00146	0.00181	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—RGS14—nephrolithiasis	0.00146	0.00181	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—PTH—nephrolithiasis	0.00145	0.0018	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—DGKH—nephrolithiasis	0.00144	0.00178	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00144	0.00178	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00143	0.00177	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—PTH—nephrolithiasis	0.00136	0.00168	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—PTH—nephrolithiasis	0.00134	0.00165	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00133	0.00164	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—APRT—nephrolithiasis	0.00132	0.00164	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—SLC26A1—nephrolithiasis	0.00132	0.00164	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—PTH—nephrolithiasis	0.00131	0.00162	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—DGKH—nephrolithiasis	0.0013	0.00161	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.0013	0.00161	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—CHRM3—nephrolithiasis	0.0013	0.00161	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—PTH—nephrolithiasis	0.00122	0.0015	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—DGKH—nephrolithiasis	0.00121	0.0015	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00121	0.0015	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.00121	0.00149	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—DGKH—nephrolithiasis	0.00119	0.00148	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00119	0.00148	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—PTH—nephrolithiasis	0.00119	0.00147	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—AQP1—nephrolithiasis	0.00116	0.00144	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—PTH—nephrolithiasis	0.0011	0.00136	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—DGKH—nephrolithiasis	0.00106	0.00131	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00106	0.00131	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—CHRM3—nephrolithiasis	0.00105	0.0013	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CHRM3—nephrolithiasis	0.00104	0.00129	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000986	0.00122	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—DGKH—nephrolithiasis	0.000986	0.00122	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PTH—nephrolithiasis	0.000952	0.00118	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—AQP1—nephrolithiasis	0.000942	0.00117	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CHRM3—nephrolithiasis	0.000939	0.00116	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CHRM3—nephrolithiasis	0.000877	0.00109	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CHRM3—nephrolithiasis	0.000863	0.00107	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PTH—nephrolithiasis	0.000859	0.00106	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—CHRM3—nephrolithiasis	0.000852	0.00105	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PTH—nephrolithiasis	0.000802	0.000993	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PTH—nephrolithiasis	0.00079	0.000977	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CHRM3—nephrolithiasis	0.000767	0.000949	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000713	0.000882	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PTH—nephrolithiasis	0.000701	0.000868	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PTH—nephrolithiasis	0.000652	0.000806	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—SPP1—nephrolithiasis	0.000478	0.000591	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—SPP1—nephrolithiasis	0.000431	0.000534	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—SPP1—nephrolithiasis	0.000403	0.000498	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—SPP1—nephrolithiasis	0.000396	0.00049	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SPP1—nephrolithiasis	0.000352	0.000436	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SPP1—nephrolithiasis	0.000327	0.000405	CbGpPWpGaD
